BEERSE, BELGIUM, March 10, 2026 (GLOBE NEWSWIRE) — Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication extension of TECVAYLI®▼(teclistamab) as monotherapy for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received...

Aarhus, Denmark – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, announces today a poster and late-breaking oral presentation describing safety and efficacy data from its Phase 2a SYNAPSE-CMT study evaluating ignaseclant (formerly known as NMD670) in patients living with Charcot-Marie-Tooth disease...

SEATTLE, WA – Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients who are either elderly or unfit for...